Last reviewed · How we verify
NCT05231161: UZ Clear
Diagnostic Performance of Exercise Stress Tests for the Detection of Epicardial and Microvascular Coronary Artery Disease
trial testing Index of Microvascular Resistance in Coronary Artery Disease in 114 participants. Completed in 31 December 2021.
1 November 2021
Quick facts
| Lead sponsor | Onze Lieve Vrouw Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 114 |
| Start date | 1 December 2019 |
| Primary completion | 1 November 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Index of Microvascular Resistance
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Onze Lieve Vrouw Hospital
Who can join
Adults 18 to 80, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective, single-arm, multicenter study of patients with an intermediate pre-test probability of CAD and positive exercise stress tests referred for invasive angiography. Patients underwent an invasive diagnostic procedure (IDP) with measurement of fractional flow reserve (FFR) and index of microvascular resistance (IMR) in at least one coronary vessel. The objective was to determine the false discovery rate (FDR) of cardiac exercise stress tests with both FFR and IMR as references.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05231161
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Onze Lieve Vrouw Hospital trials
Trials by the same sponsor.
- NCT05117853 — Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Thyroidectomy · Phase 3 · recruiting
- NCT03782688 — Precise Percutaneous Coronary Intervention Plan (P3) Study · completed
- NCT03778749 — Electromyography and Acceleromyography in Ventilated ICU Patients · NA · terminated
- NCT03665805 — Postoperative Residual Curarization in 2018 · completed
- NCT03824600 — Physiological Patterns of Coronary Artery Disease · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05231161 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Onze Lieve Vrouw Hospital
- Last refreshed: 9 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05231161.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing